Free adult web cames
Adding to its drug arsenal, Blumberg researchers have used computer modeling to design and produce targeted drugs against hepatitis B and liver cancer.
In another innovative approach, researchers are screening plant and fungal extracts from its Natural Products Collection, donated by Merck & Co.
They have limited effectiveness against ccc DNA, the seemingly indestructible “mini-chromosome” of the hepatitis B virus that continues to produce virus particles in infected liver cells, even in people being treated.
A cure, therefore, would have to destroy or silence ccc DNA and provide long-term immunity.
= new Date(); Time((new Date()).value Of() - 1000*60*60*24*90); self.new_streams = (Full Year() * 10000 (Month() 1) * 100 Date()); self.bwidth = window.inner Width; self.online = /* this overrides everything for males only cobrands */ var malefilters = self.my_filter = function (el) var attach_studio = ''; var region = ''; var reg_boost = 10; self.cobrand_boosts = var voy_time = ; var priv_time = ; self.gender_filter_cookie_name = 'webcam_gender_filter'; self.set_my_gender_cookie = function (gender) self.check_gender = function()(); self.get_my_gender_cookie = function () self.debugg = 0; self.show_ts = 1; var cams = ; self.won_from_json = function (a) , 'o' : function (a, b) , 's' : function (a, b) , 'v' : function(a,b) , 'z' : function(a,b) , 'F' : function(a,b) , 'h' : function(a,b) , 'G' : function(a,b) } self.dislike = function (a,e) var ref = ; for (var i in cat_counts) var myyank = yank(parent); for (var i in ref) myyank(); } } self.won_url = '/lvswon.cgi?
“We are committing everything we have, every resource at our disposal, to developing the therapies that will ultimately improve the lives of all people living with hepatitis B worldwide and ultimately relegate hepatitis B to the history books.” Drugs currently in development at the Blumberg Institute ccc DNA Inhibitors: Blumberg is the only group to identify the first small molecule inhibitor of HBV ccc DNA, which has now been made highly active and is licensed to Arbutus Biopharma for further development.
Capsid Inhibitors, “YES Kinase” Inhibitors: It is using high-throughput screens and computer modeling to design and produce targeted drugs that include capsid inhibitors for hepatitis B and “YES kinase” inhibitors for liver cancer.
Immune System Activators: It has developed a new HBV drug that works by activating an infected liver cell’s own immune system, which has been shown to be effective in animal studies.
Natural Antiviral Agents: It has screened thousands of plant and fungal extracts from our extensive Natural Products Collection and identified two new leads that show potential activity against HBV.